IFN-α armed gE elicits superior immunogenicity compared to unmodified antigens and flagellin armed gE in mice
© 2024 The Authors..
Herpes zoster (HZ) induces significant pain and discomfort, which can seriously affect the quality of life of patients. At present, there is no specific treatment for HZ, and the mosteffective HZ control is vaccination. The main obstacle to developing an effective HZ vaccine is poorly induced cellular immune response. In this study, the IFN-α-gE-Fc fusion protein induced higher levels of humoral and cellular immunity compared to the unengineered gE antigen and higher levels of cellular immunity compared to the flagellin-gE-Fc fusion protein in a murine model. Compared with the marketed recombinant herpes zoster vaccine (Shingrix), IFN-α-gE-Fc can replace current used MPL adjuvant. At the same time, the immunogenicity of the IFN-α-gE-Fc + AQ was not weaker than that of the marketed recombinant zoster vaccine. The novel fusion protein provides a candidate entity for the development of a safe and effective novel HZ vaccine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Vaccine: X - 17(2024) vom: 26. Feb., Seite 100432 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Jiangang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Glycoprotein E |
|---|
| Anmerkungen: |
Date Revised 02.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jvacx.2024.100432 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367885093 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367885093 | ||
| 003 | DE-627 | ||
| 005 | 20240202232247.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240201s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jvacx.2024.100432 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1278.xml |
| 035 | |a (DE-627)NLM367885093 | ||
| 035 | |a (NLM)38299205 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Jiangang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IFN-α armed gE elicits superior immunogenicity compared to unmodified antigens and flagellin armed gE in mice |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. | ||
| 520 | |a Herpes zoster (HZ) induces significant pain and discomfort, which can seriously affect the quality of life of patients. At present, there is no specific treatment for HZ, and the mosteffective HZ control is vaccination. The main obstacle to developing an effective HZ vaccine is poorly induced cellular immune response. In this study, the IFN-α-gE-Fc fusion protein induced higher levels of humoral and cellular immunity compared to the unengineered gE antigen and higher levels of cellular immunity compared to the flagellin-gE-Fc fusion protein in a murine model. Compared with the marketed recombinant herpes zoster vaccine (Shingrix), IFN-α-gE-Fc can replace current used MPL adjuvant. At the same time, the immunogenicity of the IFN-α-gE-Fc + AQ was not weaker than that of the marketed recombinant zoster vaccine. The novel fusion protein provides a candidate entity for the development of a safe and effective novel HZ vaccine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Glycoprotein E | |
| 650 | 4 | |a Herpes zoster | |
| 650 | 4 | |a Interferon-α | |
| 650 | 4 | |a Vaccine | |
| 700 | 1 | |a Peng, Shaodan |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Qiao, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Xiaoke |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Xiaolong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yueran |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Zhongqi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Si, Weixue |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine: X |d 2019 |g 17(2024) vom: 26. Feb., Seite 100432 |w (DE-627)NLM299955931 |x 2590-1362 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2024 |g day:26 |g month:02 |g pages:100432 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jvacx.2024.100432 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2024 |b 26 |c 02 |h 100432 | ||